Applied Molecular Transport (AMT) has entered into a research collaboration and license agreement granting Janssen Biotech an exclusive, worldwide license for an orally administered biopharma candidate engineered for the treatment of inflammatory bowel diseases. AMT’s technology, TRANSINT, enables the development of oral biopharmaceuticals and RNA therapeutics for local gastrointestinal targeting or systemic release.   AMT is eligible to receive upfront license fees, support for research activit...